Divi's Labs Confirms Double-Digit H2 FY27 Revenue Growth Outlook Following 17% H1 Expansion

Market snapshot: Divi's Laboratories management has reiterated a double-digit top-line growth trajectory for the second half of FY2027. This guidance builds on a 17% constant currency expansion achieved in the first half of the fiscal year.

Data Snapshot

• H1 FY2027 Constant Currency Revenue Growth: 17%
• Q2 FY2027 Net Profit: ₹1,127 crore (up 63.6% YoY)
• Q2 FY2027 Operational Revenue: ₹3,676 crore (up 35.4% YoY)
• H1 FY2027 Total Revenue: ₹6,907 crore

What's Changed

• Management reiterated a double-digit revenue growth guidance for H2 FY2027.
• H1 FY2027 delivered 17% constant currency revenue growth across major export markets.
• Q2 FY2027 net profit rose 63.6% YoY to ₹1,127 crore on operational revenue of ₹3,676 crore.

Key Takeaways

• Management maintains visibility for sustained double-digit top-line growth in H2 FY2027.
• First-half performance was anchored by 17% constant currency growth.
• Operational expansion at core manufacturing facilities supports long-term commercial delivery.

SAHI Perspective

Divi's Laboratories' confirmation of double-digit revenue growth for H2 FY2027 reflects stable commercial traction in Custom Synthesis and core active pharmaceutical ingredient portfolios. Operational execution remains protected by backward integration initiatives.

Market Implications

Steady double-digit growth expectations support revenue visibility for CDMO and API export segments. Market focus will center on execution timelines across contract commitments in upcoming quarters.

Trading Signals

Market Bias: Bullish

Management confirmation of double-digit H2 FY2027 revenue expansion following 17% constant currency growth in H1 FY2027 highlights strong top-line sustainability.

Overweight: Pharmaceuticals, Active Pharmaceutical Ingredients (APIs), Custom Synthesis / CDMO

Trigger Factors:

• Execution on Custom Synthesis commercial supply contracts
• Maintenance of operational margins amid global API pricing dynamics
• Regulatory inspection outcomes across manufacturing sites

Time Horizon: Medium-term (3-12 months)

Industry Context

India's active pharmaceutical ingredient and custom synthesis sectors benefit from global customer supply-chain diversification. Backward integration models allow top-tier CDMO manufacturers to mitigate raw material pricing variability.

Key Risks to Watch

• Fluctuations in global generic API pricing environment
• Input cost inflation and regulatory validation timelines for new commercial plants

Recent Developments

Divi's Laboratories reported strong Q2 FY2027 results with consolidated net profit rising 63.6% YoY to ₹1,127 crore on a 35.4% increase in revenue from operations to ₹3,676 crore. This performance contributed to H1 FY2027 overall top-line expansion, providing visibility for management's double-digit growth trajectory in the second half of the fiscal year.

Closing Insight

Sustained revenue momentum in H1 FY2027 provides a grounded baseline for Divi's Laboratories as it executes against its double-digit growth targets in the second half of the fiscal year.

High Performance Trading with SAHI.